Results 91 to 100 of about 12,580 (199)

The outcomes of favipiravir exposure in pregnancy: a case series

, 2022
PURPOSE: As in vitro and in vivo studies reported antiviral efficacy against RNA viruses, favipiravir, a pyrazinecarboxamide derivative, has become one of the treatment options for COVID-19 in some countries including Turkey.
Incir, Canet, Gelal, Ayse, Kalkan, Sule, Ertem, Ozge, Guner, Ozge   +4 more
core   +1 more source

The Impact of Study Size on COVID‐19 Treatment Outcomes: A Meta‐Epidemiological Study Comparing Large and Small Randomized Controlled Trials

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Small randomized controlled trials (RCTs) in COVID‐19 meta‐analyses have been associated with more favourable treatment effects and reduced result stability. This study assessed how trial size impacts effect estimates, statistical stability, and risk of bias.
Dong Hyun Kim, Soojin Lim, Michael Eisenhut, Andreas Kronbichler, Eunyoung Kim, Min Seo Kim, Stefania I. Papatheodorou, Justin Stebbing, Yonghong Peng, Sarah Soyeon Oh, Jae Il Shin, Lee Smith   +11 more
wiley   +1 more source

Review of the Effects of Favipiravir on Filoviruses

, 2020
Objective: a review of current studies on the efficacy of favipiravir as a treatment option for Ebola and Marburg viruses. Methods: Studies were gathered from several sources, including PubMed, JSTOR, and Science Direct.
Bladholm, Bailey
core  

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease

Viruses
Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013 ...
Dylan M. Johnson, Terry Juelich, Lihong Zhang, Jennifer K. Smith, Birte K. Kalveram, David Perez, Jeanon Smith, Michael R. Grimes, Tania Garron, Maricela Torres, Shane Massey, Trevor Brasel, David W. C. Beasley, Alex N. Freiberg, Jason E. Comer   +14 more
doaj   +1 more source

Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir

Journal of Microbiology, Immunology and Infection, 2018
Background: T-705 (favipiravir) is a potent inhibitor of RNA-dependent RNA polymerases of influenza viruses and no favipiravir-resistant virus has been isolated.
Tohru Daikoku, Mineyuki Mizuguchi, Takayuki Obita, Takeshi Yokoyama, Yoshihiro Yoshida, Masaya Takemoto, Kimiyasu Shiraki   +6 more
doaj   +1 more source

f‐Block Element‐Based MOF Thin Films: A Platform for Luminescence, Sensing, and Energy Applications

Small, Volume 22, Issue 16, 17 March 2026.
f‐Block element–based metal–organic framework (f‐MOF) thin films offer exceptional potential for luminescent, sensing, and energy‐related applications. This review surveys recent progress in their synthesis, characterization, and functional implementation, emphasizing the diversity of available thin‐film fabrication strategies. The convergence of these
Dong‐Hui Chen, Christof Wöll
wiley   +1 more source

In vitro studies for BCS classification of an antiviral agent, favipiravir

, 2021
Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is a purine nucleic acid analog, which is an antiviral agent used in the treatment of influenza. Since the recent outbreak caused by 2019-novel coronavirus (nCoV), there has been a seek for effective
EROĞLU, HAKAN, Karabulut, Tutku Ceren, Atasoglu, Meltem, Oner, Yalcin, TİMUR, SELİN SEDA   +4 more
core   +1 more source

Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)

Pneumonia
Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia. Methods A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID ...
Juan P. Horcajada, Rebeca Aldonza, Mónica Real, Silvia Castañeda-Espinosa, Elena Sendra, Joan Gomez-Junyent, Inmaculada López-Montesinos, Silvia Gómez-Zorrilla, Silvia Briansó, Montserrat Duran-Taberna, Andrés Fernández, Cristina Tarragó, Teresa Auguet-Quintillá, the COVID-MAR Research group, the COVID-HJ23 group   +14 more
doaj   +1 more source

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.

, 2017
Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients.
Favié, Laurent Ma, Jean-Luc Murk, A Laura Nijstad, Maaike A Sikma, van Maarseveen, Erik M, Murk, Jean-Luc, Nijstad, A Laura, Sikma, Maaike A, Meijer, Adam, Adam Meijer, Laurent MA Favié, Erik M van Maarseveen   +11 more
core   +1 more source

Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Разработка и регистрация лекарственных средств
Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2).
T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin   +9 more
doaj   +1 more source